Companies › Khondrion
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Neurology, Infectious disease; next expected readout Sep 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sonlicromanol Mitochondrial function enhancer; CardioProtein complex I supporter | – | Phase 3 | Mitochondrial Diseases; Post COVID Condition | Sep 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07298005 | Sonlicromanol | Phase 2 | Post COVID Condition | Infectious disease | Feb 2027 |
| NCT06451757 | Sonlicromanol | Phase 3 | Mitochondrial Diseases | Neurology | Sep 2029 |
No annotated target.
–
Green Valley (Shanghai) Pharmaceuticals CereMark Pharma Tatchempharmpreparaty, JSC Carnot Laboratories Prilenia
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.